financetom
Business
financetom
/
Business
/
Asana Stock Drops 19% After Weak FY26 Guidance Despite Q1 Beat
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Asana Stock Drops 19% After Weak FY26 Guidance Despite Q1 Beat
Jun 4, 2025 1:17 PM

Asana Inc. ( ASAN ) shares are trading lower Wednesday after the company issued full-year fiscal 2026 guidance that fell well short of Wall Street expectations, overshadowing better-than-expected first-quarter earnings and revenue.

What To Know: The company reported first-quarter earnings of five cents per share, beating the consensus estimate of two cents. Revenue came in at $187.27 million, slightly above the $185.4 million estimate. The company also posted its first positive operating margin in history at 4.3% and announced its largest customer deal ever, with a $100 million contract signed in the quarter.

However, investor focus quickly shifted to the outlook. Asana guided full-year adjusted earnings to 22 cents per share, below the 33-cent estimate. It also lowered the midpoint of its revenue range to $782.5 million, compared to analyst expectations of $857.76 million. The company cited macroeconomic risks and a major deal renewal that stretched the contract term to three years but lowered the annual value.

The weaker guidance raised concerns among analysts. RBC reiterated its Underperform rating with a $10 target, noting that net revenue retention fell and billings missed expectations. JMP pointed out that while year-over-year revenue was up 9%, it declined 10% sequentially.

Despite some optimism around margin improvements and AI product traction, analysts remain cautious. Piper Sandler raised its target from $17 to $19, citing operating leverage, while JMP and KeyBanc flagged slowing momentum and macro uncertainty.

ASAN Price Action: Asana shares were down 19.7% at $15.26 at the time of writing, according to Benzinga Pro.

Read Next:

Stocks Stall On Weak Economic Data, Treasuries Eyes Best Rally In 7 Months: What’s Driving Markets Wednesday?

Image Via Shutterstock.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
OneSpaWorld Signs Service Agreements With Celebrity Cruises, Royal Caribbean International
OneSpaWorld Signs Service Agreements With Celebrity Cruises, Royal Caribbean International
Mar 12, 2024
10:47 AM EDT, 03/12/2024 (MT Newswires) -- OneSpaWorld Holdings ( OSWWF ) said Tuesday it signed new multi-year agreements with Celebrity Cruises and Royal Caribbean Group's (RCL) Royal Caribbean International unit to provide its services across Celebrity Cruises and Royal Caribbean fleets. The company said the deals will cover wellness, beauty, acupuncture, medi-spa, and fitness services. No financial details were...
Boeing whistleblower found dead of apparent suicide
Boeing whistleblower found dead of apparent suicide
Mar 12, 2024
(Reuters) - John Barnett, a former Boeing employee who had reportedly raised concerns about the company's production issues, was found dead of an apparent suicide, according to authorities in South Carolina. Barnett had worked at Boeing ( BA ) for 32 years before leaving the company in 2017, according to the BBC, which previously reported on his efforts to raise...
Reunion Gold Announces Acceptance of Terms of Scope for Environmental and Social Impact Assessment on Oko West Project
Reunion Gold Announces Acceptance of Terms of Scope for Environmental and Social Impact Assessment on Oko West Project
Mar 12, 2024
10:52 AM EDT, 03/12/2024 (MT Newswires) -- Reunion Gold Corporation ( RGDFF ) says the Environmental Protection Agency (EPA) of Guyana has finalized and approved the Terms of Scope (ToS) for the Environmental and Social Impact Assessment (ESIA) on the Oko West Project in Guyana's Region 7. The ToS is required for Reunion to move forward with work on the...
Genprex Awarded South Korean Patent for Drug Candidate Reqorsa Plus Antibodies to Treat Cancers
Genprex Awarded South Korean Patent for Drug Candidate Reqorsa Plus Antibodies to Treat Cancers
Mar 12, 2024
10:51 AM EDT, 03/12/2024 (MT Newswires) -- Genprex ( GNPX ) said Tuesday that South Korea's Patent Office has issued it a patent covering the use of its Reqorsa Immunogene Therapy lead drug candidate in combination with anti-PD-1 and PD-L1 antibodies through 2037 to treat cancers. The patent is applicable to the company's Acclaim-2 and Acclaim-3 trials, Genprex ( GNPX...
Copyright 2023-2026 - www.financetom.com All Rights Reserved